Document Detail


Non-Invasive Assessment of Non-alcoholic Fatty Liver Disease in Obese or Overweight Patients.
MedLine Citation:
PMID:  22796457     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND AND AIMS: Reliable non-invasive tools are needed for staging non-alcoholic fatty liver disease (NAFLD). Published scoring systems have not been validated in prospective assessments of unselected patients. We aimed to identify factors that predicted development of non-alcoholic steatohepatitis (NASH) in a large group of overweight or obese patients and compared these with established factors. METHODS: We performed a prospective analysis of factors associated with the development and severity of NAFLD in patients at a single obesity center. We evaluated liver involvement in 542 patients by a large set of routine and non-routine parameters, including ultrasound and genetic testing. Those suspected of having NAFLD underwent liver biopsy (57.7%). Patients were divided into design (n=200) and validation cohorts (n=113) to identify factors associated with the presence and severity of NAFLD and NASH. RESULTS: Factors independently associated with development of NASH included increased levels of alanine aminotransferase (ALT), fasting levels of C-peptide, and ultrasound steatosis scores (USSs), with area under the receiver operating curve (AUROC) values of 0.854 in the design cohort and 0.823 in the validation cohort. NASH activity scores also correlated with level of ALT, USS, and fasting level of C-peptide (R2=0.491). Independent predictors of advanced fibrosis included waist circumference and level of aspartate aminotransferase (AUROC values of 0.839 and 0.846 for design and validation cohorts; negative predictive values of 98% and 97% for a cut off of -2.14). Previously published scoring systems had significantly lower AUROC values. Levels of CK18 and PNPLA3 polymorphisms correlated with development of NASH but did not add value. CONCLUSIONS: Parameters routinely analyzed in assessing obese patients can be used to determine the presence of NASH and advanced fibrosis. Non-routine tests do not increase diagnostic accuracy. Previously published scores are significantly less accurate.
Authors:
Sven Francque; An Verrijken; Ilse Mertens; Guy Hubens; Eric Van Marck; Paul Pelckmans; Peter Michielsen; Luc Van Gaal
Related Documents :
22078397 - Prevalence of atrial fibrillation in patients with history of paroxysmal supraventricul...
15526917 - Therapeutic apheresis of immune diseases in nephrology department.
21951407 - Can stroke cause neurodegenerative dementia?
10855557 - High level of lipoprotein(a) is a strong predictor for progression of coronary artery d...
3457897 - A study of histocompatibility antigens in patients with motor neuron disease in the nor...
18675217 - Heart rate turbulence predicts all-cause mortality and sudden death in congestive heart...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-12
Journal Detail:
Title:  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association     Volume:  -     ISSN:  1542-7714     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160775     Medline TA:  Clin Gastroenterol Hepatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ?(2)-Adrenoceptors and muscarinic receptors mediate opposing effects on endothelin-1 expression in h...
Next Document:  Targeting BRAF(V600E) in an Inducible Murine Model of Melanoma.